Krystal Biotech makes VYJUVEK — the first FDA-approved redosable gene therapy — a gel that delivers working collagen-VII genes into the skin of dystrophic epidermolysis bullosa patients. It designs, manufactures (in its own Pittsburgh plants) and sells the medicine itself, turning a single rare-disease drug into a ~$389M, 94%-gross-margin, profitable franchise while a broad pipeline rides the same redosable HSV-1 platform.
What Krystal Biotech, Inc. really sells
Krystal Biotech makes VYJUVEK — the first FDA-approved redosable gene therapy — a gel that delivers working collagen-VII genes into the skin of dystrophic epidermolysis bullosa patients. It designs, manufactures (in its own Pittsburgh plants) and sells the medicine itself, turning a single rare-disease drug into a ~$389M, 94%-gross-margin, profitable franchise while a broad pipeline rides the same redosable HSV-1 platform.